Topas Therapeutics

Topas Therapeutics, Eli Lilly ink agreement on immune tolerance

Friday, August 25, 2017

Topas Therapeutics, a Hamburg, Germany-based private company, has signed a multi-year agreement with Eli Lilly to collaborate in the field of antigen-specific tolerance induction with an initial focus on external antigens thought to induce inflammation and/or autoimmune disease. Topas will be responsible for conducting pre-clinical proof-of-principle studies in collaboration with Lilly to generate drug candidates. Under the terms of the agreement, Lilly has an option for all candidates produced under the collaboration for in-licensing and further development. Topas will receive R&D funding and participate in the future success of any compounds in-licensed by Lilly. Financial details of the collaboration are not being disclosed.

[Read More]